-
1 Comment
Osmotica Pharmaceuticals plc is currently in a long term downtrend where the price is trading 31.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.2.
Osmotica Pharmaceuticals plc's total revenue sank by 42.4% to $35M since the same quarter in the previous year.
Its net income has dropped by 106.0% to $-55M since the same quarter in the previous year.
Finally, its free cash flow fell by 2969.4% to $-9M since the same quarter in the previous year.
Based on the above factors, Osmotica Pharmaceuticals plc gets an overall score of 1/5.
| CurrencyCode | USD |
|---|---|
| Exchange | NASDAQ |
| ISIN | IE00BF2HDL56 |
| Industry | Pharmaceuticals |
| Sector | Healthcare |
| Target Price | 5.75 |
|---|---|
| Beta | 1.96 |
| Dividend Yield | 0.0% |
| PE Ratio | None |
| Market Cap | 92M |
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for OSMT using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
